Shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.54 and last traded at $1.51, with a volume of 5,432,543 shares trading hands. The stock had previously closed at $5.33.

A number of analysts have issued reports on the stock. Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, June 5th. ValuEngine upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Stifel Nicolaus cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $15.00 to $2.50 in a research note on Monday. Piper Jaffray Companies restated an “overweight” rating and issued a $18.00 price objective (up from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Finally, Needham & Company LLC cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $10.23.

The firm’s market cap is $34.06 million. The stock’s 50 day moving average is $4.75 and its 200 day moving average is $5.55.

Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). On average, equities research analysts forecast that Genocea Biosciences, Inc. will post ($1.92) earnings per share for the current fiscal year.

In other news, CFO Jonathan Poole sold 45,000 shares of Genocea Biosciences stock in a transaction on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the sale, the chief financial officer now owns 84,247 shares of the company’s stock, valued at $505,482. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.70% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of GNCA. GSA Capital Partners LLP bought a new position in shares of Genocea Biosciences in the second quarter worth $100,000. Ameriprise Financial Inc. grew its position in Genocea Biosciences by 11.5% in the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 2,300 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Genocea Biosciences in the second quarter valued at about $125,000. Keybank National Association OH bought a new position in Genocea Biosciences in the first quarter valued at about $147,000. Finally, Rhumbline Advisers bought a new position in Genocea Biosciences in the second quarter valued at about $157,000. Institutional investors own 59.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/28/genocea-biosciences-inc-gnca-hits-new-52-week-low-at-1-54.html.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.